Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures

Journal of Neuroimmunology

Volumn 185, Issue 1-2, 2007, Pages 136-144

  Farrugia, Maria Elena ^a   Bonifati, Domenico Marco ^a   Clover, Linda ^a   Cossins, Judy ^a   Beeson, David ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetylcholine receptor; Muscle specific tyrosine kinase (MuSK); Myasthenia gravis; Seronegative myasthenia gravis

Indexed keywords

AGRIN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; MESSENGER RNA; MUSCLE SPECIFIC KINASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYASTHENIA GRAVIS; MYOTUBE; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; UPREGULATION;

ANIMALS; AUTOANTIBODIES; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOGLOBULIN G; MICE; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33947697779     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.01.010     Document Type: Article

References (38)

1. Beeson D., Higuchi O., Palace J., Cossins J., Spearman H., Maxwell S., Newsom-Davis J., Burke G., Fawcett P., Motomura M., Muller J.S., Lochmuller H., Slater C., Vincent A., and Yamanashi Y. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313 (2006) 1975-1978
2. Benveniste O., Jacobson L., Farrugia M.E., Clover L., and Vincent A. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J. Neuroimmunol. 170 (2005) 41-48
3. Boneva N., Frenkian-Cuvelier M., Bidault J., Brenner T., and Berrih-Aknin S. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis. J. Neuroimmunol. 177 (2006) 119-131
4. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., and Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7297-7301
5. Burges J., Wray D.W., Pizzighella S., Hall Z., and Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 13 (1990) 407-413
6. Burges J., Vincent A., Molenaar P.C., Newsom-Davis J., Peers C., and Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 17 (1994) 1393-1400
7. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., Kinetz E., Compton D.L., Rojas E., Park J.S., Smith C., DiStefano P.S., Glass D.J., Burden S.J., and Yancopoulos G.D. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85 (1996) 501-512
8. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., and Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 298 (1978) 1116-1122
9. Engel A.G., Lambert E.H., and Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52 (1977) 267-280
10. Fambrough D.M., Devreotes P.N., Gardner J.M., and Card D.J. The life history of acetylcholine receptors. Prog. Brain Res. 49 (1979) 325-334
11. Farrugia M.E., Robson M.D., Clover L., Anslow P., Newsom-Davis J., Kennett R., Hilton-Jones D., Matthews P.M., and Vincent A. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129 (2006) 1481-1492
12. Ferns M.J., Campanelli J.T., Hoch W., Scheller R.H., and Hall Z. The ability of agrin to cluster AChRs depends on alternative splicing and on cell surface proteoglycans. Neuron 11 (1993) 491-502
13. Frail D.E., McLaughlin L.L., Mudd J., and Merlie J.P. Identification of the mouse muscle 43,000-dalton acetylcholine receptor-associated protein (RAPsyn) by cDNA cloning. J. Biol. Chem. 263 30 (1988) 15602-15607
14. Froehner S.C. The submembrane machinery for nicotinic acetylcholine receptor clustering. J. Cell Biol. 114 (1991) 1-7
15. Fuhrer C., Gaurtam M., Sugiyama J.E., and Hall Z.W. Roles of rapsyn and agrin in interaction of postsynaptic proteins with acetylcholine receptors. J. Neurosci. 19 (1999) 6405-6416
16. Gautam M., Noakes P.G., Mudd J., Nichol M., Chu G.C., Sanes J.R., and Merlie J.P. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 377 (1995) 232-236
17. Gautam M., Noakes P.G., Moscoso L., Rupp F., Scheller R.H., Merlie J.P., and Sanes J.R. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85 (1996) 525-535
18. Glass D.J., DeChiara T.M., Stitt T.N., DiStefano P.S., Valenzuela D.M., and Yancopoulos G.D. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. Cold Spring Harbor Symp. Quant. Biol. 61 (1996) 435-444
19. Guyon T., Levasseur P., Truffault F., Cottin C., Gaud C., and Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J. Clin. Invest. 94 (1994) 16-24
20. Guyon T., Wakkach A., Poea S., Mouly V., Klingel-Schmitt I., Levasseur P., Beeson D., Asher O., Tzartos S., and Berrih-Aknin S. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J. Clin. Invest. 102 (1998) 249-263
21. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
22. Jha S., Xu K., Maruta T., Oshima M., Mosier D.R., Atassi M.Z., and Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175 (2006) 107-117
23. Kong X.C., Barzaghi P., and Ruegg M.A. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 5 (2004) 183-188
24. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., Niks E.H., Berrih-Aknin S., Scaravilli F., Canelhas A., Marx A., Newsom-Davis J., Willcox N., and Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann. Neurol. 57 (2005) 444-448
25. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
26. Marangi P.A., Wieland S.T., and Fuhrer C. Laminin-1 redistributes postsynaptic proteins and requires rapsyn, tyrosine phosphorylation, and Src and Fyn to stably cluster acetylcholine receptors. J. Cell Biol. 157 (2002) 883-895
27. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., and Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55 (2004) 580-584
28. Moransard M., Borges L.S., Willmann R., Marangi P.A., Brenner H.R., Ferns M.J., and Fuhrer C. Agrin regulates rapsyn interaction with surface acetylcholine receptors, and this underlies cytoskeletal anchoring and clustering. J. Biol. Chem. 278 (2003) 7350-7359
29. Mossman S., Vincent A., and Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1 (1986) 116-119
30. Ohta K., Shigemoto K., Kubo S., Maruyama N., Abe Y., Ueda N., and Ohta M. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 62 (2004) 2132-2133
31. Poea S., Guyon T., Bidault J., Bruand C., Mouly V., and Berrih-Aknin S. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis. Ann. Neurol. 48 (2000) 696-705
32. Selcen D., Fukuda T., Xin-Ming S., and Engel A. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 62 (2004) 1945-1950
33. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., Kobayashi N., Mominoki K., Abe Y., Ueda N., and Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 116 (2006) 1016-1024
34. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., and Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 57 (2005) 289-293
35. Silberstein L., Webster S.G., Travis M., and Blau H.M. Developmental progression of myosin gene expression in cultured muscle cells. Cell 46 (1986) 1075-1081
36. Spreadbury I., Kishore U., Beeson D., and Vincent A. Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation. J. Neuroimmunol. 162 (2005) 149-156
37. Tzartos S.J., Sophianos D., Zimmerman K., and Starzinski-Powitz A. Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate. J. Immunol. 136 (1986) 3231-3238
38. Vincent A., and Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18 (2005) 519-525